TY - JOUR
T1 - Attributable mortality and excess length of stay associated with third-generation cephalosporin-resistant Enterobacterales bloodstream infections
T2 - a prospective cohort study in Suva, Fiji
AU - Loftus, Michael J.
AU - Young-Sharma, Tracey E.M.W.
AU - Lee, Sue J.
AU - Wati, Shitanjni
AU - Badoordeen, Gnei Z.
AU - Blakeway, Luke V.
AU - Byers, Sally M.H.
AU - Cheng, Allen C.
AU - Cooper, Ben S.
AU - Cottingham, Hugh
AU - Jenney, Adam W.J.
AU - Hawkey, Jane
AU - Macesic, Nenad
AU - Naidu, Ravi
AU - Prasad, Amitesh
AU - Prasad, Vinita
AU - Tudravu, Litia
AU - Vakatawa, Timoci
AU - van Gorp, Elke
AU - Wisniewski, Jessica A.
AU - Rafai, Eric
AU - Peleg, Anton Y.
AU - Stewardson, Andrew J.
N1 - Funding Information:
MJL, NM, AJS, and AYP are supported by Australian National Health and Medical Research Council Postgraduate Scholarship ( APP1169220 ), Emerging Leader 1 Fellowship ( APP1176324 ), Early Career Fellowship ( GNT1141398 ), and Practitioner Fellowship ( APP1117940 ), respectively. The GRAM (Global Research on Antimicrobial Resistance) Project at Oxford University provided funding to support data collection in Suva. The GRAM project has been funded by the United Kingdom's Department of Health and Social Care, Fleming Fund, the Wellcome Trust (209142/Z/17/Z), and the Bill and Melinda Gates Foundation ( OPP1176062 ).
Funding Information:
MJL, NM, AJS, and AYP are supported by Australian National Health and Medical Research Council Postgraduate Scholarship (APP1169220), Emerging Leader 1 Fellowship (APP1176324), Early Career Fellowship (GNT1141398), and Practitioner Fellowship (APP1117940), respectively. The GRAM (Global Research on Antimicrobial Resistance) Project at Oxford University provided funding to support data collection in Suva. The GRAM project has been funded by the United Kingdom's Department of Health and Social Care, Fleming Fund, the Wellcome Trust (209142/Z/17/Z), and the Bill and Melinda Gates Foundation (OPP1176062). None declared. Ethics approval was provided by the Alfred Hospital Ethics Committee (593/19) and the Fiji National Health Research Ethics Review Committee (88/2019). Both committees granted a waiver of patient consent.
Publisher Copyright:
© 2022 The Authors
PY - 2022/9
Y1 - 2022/9
N2 - Objectives: There are scant primary clinical data on antimicrobial resistance (AMR) burden from low- and middle-income countries (LMICs). We adapted recent World Health Organization methodology to measure the effect of third-generation cephalosporin resistance (3GC-R) on mortality and excess length of hospital stay in Fiji. Methods: We conducted a prospective cohort study of inpatients with Enterobacterales bloodstream infections (BSIs) at Colonial War Memorial Hospital, Suva. We used cause-specific Cox proportional hazards models to estimate the effect of 3GC-R on the daily risk (hazard) of in-hospital mortality and being discharged alive (competing risks), and we used multistate modelling to estimate the excess length of hospital stay. Results: From July 2020 to February 2021 we identified 162 consecutive Enterobacterales BSIs; 3GC-R was present in 66 (40.7%). Crude mortality for patients with 3GC-susceptible and 3GC-R BSIs was 16.7% (16/96) and 30.3% (20/66), respectively. 3GC-R was not associated with the in-hospital mortality hazard rate (adjusted hazard ratio [aHR] 1.13, 95% confidence interval [CI] 0.51–2.53) or being discharged alive (aHR 0.99, 95% CI 0.65–1.50), whereas Charlson comorbidity index score (aHR 1.62, 95% CI 1.36–1.93) and Pitt bacteraemia score (aHR 3.57, 95% CI 1.31–9.71) were both associated with an increased hazard rate of in-hospital mortality. 3GC-R was associated with an increased length of stay of 2.6 days (95% CI 2.5–2.8). 3GC-R was more common among hospital-associated infections, but genomics did not identify clonal transmission. Conclusion: Patients with Enterobacterales BSIs in Fiji had high mortality. There were high rates of 3GC-R, which was associated with increased hospital length of stay but not with in-hospital mortality.
AB - Objectives: There are scant primary clinical data on antimicrobial resistance (AMR) burden from low- and middle-income countries (LMICs). We adapted recent World Health Organization methodology to measure the effect of third-generation cephalosporin resistance (3GC-R) on mortality and excess length of hospital stay in Fiji. Methods: We conducted a prospective cohort study of inpatients with Enterobacterales bloodstream infections (BSIs) at Colonial War Memorial Hospital, Suva. We used cause-specific Cox proportional hazards models to estimate the effect of 3GC-R on the daily risk (hazard) of in-hospital mortality and being discharged alive (competing risks), and we used multistate modelling to estimate the excess length of hospital stay. Results: From July 2020 to February 2021 we identified 162 consecutive Enterobacterales BSIs; 3GC-R was present in 66 (40.7%). Crude mortality for patients with 3GC-susceptible and 3GC-R BSIs was 16.7% (16/96) and 30.3% (20/66), respectively. 3GC-R was not associated with the in-hospital mortality hazard rate (adjusted hazard ratio [aHR] 1.13, 95% confidence interval [CI] 0.51–2.53) or being discharged alive (aHR 0.99, 95% CI 0.65–1.50), whereas Charlson comorbidity index score (aHR 1.62, 95% CI 1.36–1.93) and Pitt bacteraemia score (aHR 3.57, 95% CI 1.31–9.71) were both associated with an increased hazard rate of in-hospital mortality. 3GC-R was associated with an increased length of stay of 2.6 days (95% CI 2.5–2.8). 3GC-R was more common among hospital-associated infections, but genomics did not identify clonal transmission. Conclusion: Patients with Enterobacterales BSIs in Fiji had high mortality. There were high rates of 3GC-R, which was associated with increased hospital length of stay but not with in-hospital mortality.
KW - Antimicrobial resistance
KW - Bloodstream infection
KW - Enterobacterales
KW - Fiji
KW - Mortality
UR - http://www.scopus.com/inward/record.url?scp=85135104858&partnerID=8YFLogxK
U2 - 10.1016/j.jgar.2022.06.016
DO - 10.1016/j.jgar.2022.06.016
M3 - Article
C2 - 35738385
AN - SCOPUS:85135104858
SN - 2213-7165
VL - 30
SP - 286
EP - 293
JO - Journal of Global Antimicrobial Resistance
JF - Journal of Global Antimicrobial Resistance
ER -